文献速递消化、代谢与肾脏急症

米非司酮治疗美国男性退伍军人创伤后应激障碍的疗效与安全性:2a期随机临床试验

Efficacy and Safety of Mifepristone in the Treatment of Male US Veterans With Posttraumatic Stress Disorder: A Phase 2a Randomized Clinical Trial.
PubMed 文献 · JAMA Netw Open · 2023-05-01
一句话结论在慢性创伤后应激障碍男性退伍军人中,口服米非司酮600 mg/d共7天未检出疗效信号,不支持在该人群开展3期试验。

这项2a期双盲平行组随机临床试验在美国退伍军人事务部系统内开展,纳入临床医生用创伤后应激障碍量表筛查评分≥50的慢性创伤后应激障碍男性退伍军人,按1:1随机接受米非司酮600 mg或匹配安慰剂口服7天。共81例入组,改良意向性治疗分析纳入80例(米非司酮组41例、安慰剂组39例)。4周时米非司酮组临床应答者比例为38.1%,安慰剂组为31.1%,组间差异7.0%,低于预设的15%疗效信号界值。探索性分析中,无终生创伤性脑损伤史亚组的4周应答差异为22.7%(50.0% vs 27.3%),超过疗效界值并在12周维持;有终生创伤性脑损伤史者12周时米非司酮组应答率低于安慰剂组(27.4% vs 48.3%,差异-20.9%)。作者认为该研究不支持在该人群开展3期试验,未来研究可能关注无创伤性脑损伤史者或终生头部创伤基础率低的样本。

要点

  • 慢性创伤后应激障碍男性退伍军人中,米非司酮600 mg/d口服7天在4周时临床应答率38.1% vs 安慰剂31.1%,组间差异7.0%,未达预设15%疗效信号界值。
  • 探索性亚组:无终生创伤性脑损伤史者4周应答差异22.7%(50.0% vs 27.3%),超过疗效界值并在12周维持。
  • 有终生创伤性脑损伤史者12周时米非司酮组应答率27.4% vs 安慰剂组48.3%,差异-20.9%。
  • 作者结论:本研究未检出米非司酮600 mg/d共1周在慢性创伤后应激障碍男性退伍军人中的疗效信号,不支持在该人群开展3期试验。
  • 作者认为未来米非司酮治疗创伤后应激障碍的研究可能关注无创伤性脑损伤史者或终生头部创伤基础率低的样本。

适用人群与场景

  • 美国退伍军人事务部系统内的慢性创伤后应激障碍男性退伍军人,筛查时临床医生用创伤后应激障碍量表评分≥50。
  • 共181名退伍军人同意参与,最终81名入组并随机化。

诊断标准与关键阈值

  • 筛查临床医生用创伤后应激障碍量表(Clinician-Administered PTSD Scale)评分≥50。
  • 临床应答定义为临床医生用创伤后应激障碍量表总分较基线下降≥30%,在4周和12周随访时评估。
  • 预设疗效信号界值:治疗组与对照组应答者比例差异达15%为临床相关差异。

处置流程与药物剂量

  • 米非司酮600 mg口服,每日一次,共7天;对照为匹配安慰剂。
  • 随机化按1:1比例分配。

研究设计与关键结果

  • 2a期双盲平行组随机临床试验,2012年11月19日开始入组至2016年11月16日末次随访,在美国退伍军人事务部系统内开展;81例入组随机,排除1例错误随机者,改良意向性治疗分析纳入80例(米非司酮组41例、安慰剂组39例),平均(SD)年龄43.1(13.7)岁。
  • 4周时采用多重插补分析,米非司酮组临床应答者15.6例(38.1%),安慰剂组12.1例(31.1%);组间应答比例差异7.0%,低于预设15%疗效信号界值。
  • 探索性分析:无终生创伤性脑损伤史亚组4周应答米非司酮组7.0例(50.0%)vs 安慰剂组3.0例(27.3%),差异22.7%,超过疗效界值,并在12周维持。
  • 有终生创伤性脑损伤史的创伤后应激障碍退伍军人中,12周时米非司酮组应答7.4例(27.4%)vs 安慰剂组13.5例(48.3%),差异-20.9%。

证据类型、等级与局限

  • 证据类型:2a期双盲平行组随机临床试验。

对床旁实践的改变

  • 作者结论:本研究未检出米非司酮600 mg/d共1周在慢性创伤后应激障碍男性退伍军人中的疗效信号,不支持在该人群开展3期试验。
  • 作者认为未来米非司酮治疗创伤后应激障碍的研究可能关注无创伤性脑损伤史者或终生头部创伤基础率低的样本。

指南或共识出处

  • 临床试验注册号:ClinicalTrials.gov Identifier: NCT01946685。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

IMPORTANCE: To date, no psychopharmacologic treatment has been found to be uniformly effective in veterans with posttraumatic stress disorder (PTSD); novel targets and approaches are needed to treat this disabling disorder.

OBJECTIVE: To examine whether treatment with the glucocorticoid receptor antagonist mifepristone yields a signal for clinical efficacy in male veterans with PTSD.

DESIGN, SETTING, AND PARTICIPANTS: This phase 2a, double-blind, parallel-group randomized clinical trial was conducted from November 19, 2012 (accrual started), through November 16, 2016 (final follow-up), within the US Department of Veterans Affairs. Participants were male veterans with chronic PTSD and a screening Clinician-Administered PTSD Scale score of 50 or higher. A total of 181 veterans consented to participation. Statistical analysis was conducted between August 2014 and May 2017.

INTERVENTIONS: Participants were randomized in a 1:1 ratio to mifepristone (600 mg) or matched placebo taken orally for 7 days.

MAIN OUTCOMES AND MEASURES: The clinical outcome was whether a veteran achieved a clinical response status (a reduction of ≥30% of total Clinician-Administered PTSD Scale score from baseline) at 4- and 12-week follow-up. On the basis of a binary statistical selection rule, a difference in the proportion of treatment vs control group responders of 15% would be a clinically relevant difference. Self-report measures of PTSD and associated symptoms were also obtained. Neuroendocrine outcomes and plasma levels of mifepristone were measured. Safety was assessed throughout the study. The primary analysis was based on a multiple imputation technique to address missing outcome data; thus, some participant numbers may not appear as whole numbers.

RESULTS: A total of 81 veterans were enrolled and randomized. Excluding 1 participant randomized in error, 80 were included in the modified intention-to-treat analysis (41 randomized to mifepristone and 39 to placebo). The mean (SD) age was 43.1 (13.7) years. A total of 15.6 (38.1%) in the mifepristone group and 12.1 (31.1%) in the placebo group were clinical responders at 4 weeks in the analysis using the multiple imputation technique. The group difference in the proportion of clinical responders (7.0%) was less than the predefined margin of 15% indicating signal for clinical efficacy. In an exploratory analysis, the difference in response to mifepristone vs placebo in the subgroup with no lifetime history of traumatic brain injury (TBI) (7.0 [50.0%] vs 3.0 [27.3%]; difference, 22.7%) exceeded the efficacy margin at 4 weeks and was sustained at 12 weeks. In contrast, in veterans with PTSD and lifetime TBI, the response rate to mifepristone was lower than placebo at 12 weeks (7.4 [27.4%] vs 13.5 [48.3%]; difference, -20.9%).

CONCLUSIONS AND RELEVANCE: This study did not detect a signal for efficacy for mifepristone at 600 mg/d for 1 week in male veterans with chronic PTSD. Thus, this study does not support a phase 3 trial in this population. Future studies of mifepristone for the treatment of PTSD may be of interest in those without a history of TBI or in samples with a low base rate of lifetime head trauma.

TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT01946685.

来源:JAMA Netw Open,查看原文。版权归原作者所有。

参考来源

  1. Golier JA, Li X, Bizien M, et al. Efficacy and Safety of Mifepristone in the Treatment of Male US Veterans With Posttraumatic Stress Disorder: A Phase 2a Randomized Clinical Trial. JAMA Netw Open. 2023. PMID: 37159200. doi:10.1001/jamanetworkopen.2023.10223

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。